Literature DB >> 24638002

Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.

Marie-Charlotte Loron1, Steven Grange2, Dominique Guerrot3, Frédéric Di Fiore2, Caroline Freguin2, Mélanie Hanoy2, Frank Le Roy2, Gwenaelle Poussard2, Isabelle Etienne2, Bruno Legallicier2, Christian Pfister2, Michel Godin3, Dominique Bertrand2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638002     DOI： 10.1200/JCO.2013.49.9277

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

2.  Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.

Authors:  Mélodie Carbonnaux; Yann Molin; Pierre-Jean Souquet; Arnaud Tantin; Catherine Lombard-Bohas; Thomas Walter
Journal:  Invest New Drugs       Date:  2014-08-14       Impact factor: 3.850

Review 3.  Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases.

Authors:  Sandra Assoun; Virginie Lemiale; Elie Azoulay
Journal:  Intensive Care Med       Date:  2019-05-29       Impact factor: 17.440

4.  miR149 rs71428439 polymorphism and risk of clear cell renal cell carcinoma: a case-control study.

Authors:  Zhigang Wang; Meng Wei; Yi Ren; Hua Liu; Meng Wang; Kehui Shi; Hongli Jiang
Journal:  Tumour Biol       Date:  2014-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.